Artios Pharma News and Activities
Executives
View the org chart displaying its 31 main executives
Most searched biographies at Artios Pharma
- Michael Andriole, Chief Executive Officer and Director
- Raphael Wisniewski, Director
- Michelle Doig, Director
Popular executive movements at Artios Pharma
- Guy Ruble has joined the company as Vice President, Regulatory Affairs (posted on May 5 2026).
- Jeremy Fitch has joined the company as Chief Business Officer (posted on May 5 2026).
- Michael Alrutz has joined the company as General Counsel (posted on May 5 2026).
Click here to view some more movements at Artios Pharma
Create your alert
to follow the executive moves at Artios Pharma.
Pharmaceuticals
Artios Pharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Artios Pharma
- Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer - Artios Pharma
- Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors - Artios Pharma
- Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution - Artios Pharma
- Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer - Artios Pharma
- Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer - Artios Pharma
- Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline - Artios Pharma
- Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference - Artios Pharma
- Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need - Artios Pharma
- Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 - Artios Pharma
- Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Polθ) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO - Artios Pharma
- View more press releases Close
Social media about Artios Pharma
- Artios Pharma on Wikipedia, Google News & Yahoo Finance
- Artios Pharma on LinkedIn, X (Twitter) & YouTube
